Company Overview
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Why Investors Should Care
Revenue has grown at a 85.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $50.51M (+85.9% YoY); net profit $-29.63M.
- Trailing 12 Months Year-on-year growth — revenue +58.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 85.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 85.94% |
| 1 Year: | 58.20% |
Stock Price Performance
| 1 Year: | -25.52% |
| 6 Months: | -14.89% |
| 3 Months: | +11.34% |
| 1 Month: | -7.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 85.9% over 5 years.
CONS
- Trading 36.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CARL Carlsmed, Inc. R2K | 10.80 | -11.13 | $293.60M | 0.00% | -26.39% | -52.43% | 85.94% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 6.08M | 6.59M | 10.19M | 12.08M | 13.07M | 16.12M |
| Gross Profit | - | 4.56M | 4.80M | 7.64M | 8.87M | 9.93M | 12.43M |
| Operating Income | - | -6.32M | -7.78M | -5.72M | -6.50M | -9.04M | -9.28M |
| Net Income | -5.45M | -6.28M | -7.81M | -5.73M | -6.77M | -8.53M | -8.70M |
| Diluted EPS | - | -1.55 | -2.06 | -1.47 | -1.47 | -0.40 | -0.32 |
| R&D Expense | - | 4.00M | 4.04M | 3.15M | 4.16M | 4.45M | 5.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 27.16M | 50.51M |
| Gross Profit | 20.05M | 38.04M |
| Operating Income | -24.12M | -30.57M |
| Net Income | -24.26M | -29.63M |
| Diluted EPS | -6.11 | -2.12 |
| R&D Expense | 14.30M | 17.02M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 51.82M | 130.12M |
| Total Equity | -46.13M | -70.63M | 98.87M |
| Cash & Equivalents | 7.22M | 40.12M | 85.79M |
| Long Term Debt | - | 15.41M | 15.35M |
| Total Liabilities | - | 26.23M | 31.25M |
| Current Liabilities | - | 8.82M | 14.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -25.47M | -28.98M |
| Investing Cash Flow | -180.00K | -25.48M |
| Financing Cash Flow | 58.50M | 100.13M |
| Capital Expenditure | -180.00K | -642.00K |
| Free Cash Flow | -25.65M | -29.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 73.8% | 75.3% |
| Operating Margin % | -88.8% | -60.5% |
| Net Margin % | -89.3% | -58.7% |
| ROE % | 34.3% | -30.0% |
| ROCE % | -56.1% | -26.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 4.61% | 1.25M | $14.69M |
| 2 | Janus Henderson Group PLC | 4.52% | 1.23M | $14.40M |
| 3 | Parkman Healthcare Partners LLC | 1.92% | 521.12K | $6.11M |
| 4 | Blackrock Inc. | 1.64% | 446.89K | $5.24M |
| 5 | Schonfeld Strategic Advisors Llc | 1.04% | 283.18K | $3.32M |
| 6 | Vanguard Capital Management LLC | 1.02% | 276.13K | $3.24M |
| 7 | KCM Capital Inc | 0.74% | 200.00K | $2.35M |
| 8 | Geode Capital Management, LLC | 0.71% | 193.17K | $2.27M |
| 9 | Russell Investments Group, Ltd. | 0.59% | 159.29K | $1.87M |
| 10 | State Street Corporation | 0.42% | 113.72K | $1.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CARL
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPMjN3bThBVjNjNkRTcnUzREJuLVUyYXV4dEIzTWgwV1AwT1RVOEFCNlk1a0VnX25OM2tBaV9BV3M2MjhmWVlzZXlUcGs4WXF6b05xUTRvMW9KVFRnTmpCTllIMEFzNWFqZlFwSlhwUkJyNVE5OHp5R3NVeFhyV1FnRkROaXc5YUYtZE9NQ0…
Carlsmed, Inc. Actuals & Estimates (NASDAQ:CARL) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNTUlJcUFXQ1NuTUlRMnppeGxER2RQLTBLejJwQWcwN0tTWXFBYUZ6OFh5Yl80dW1Sb1dyeWtXMGlPc1ZRU3pzME1Rbm9veDJtbm9HcG1qZ2Vud1hzQUdCNGFOZ0FJVHZMUlhnano5TnRfTGxZNHlBT0plaTBUYm5Qem5JaVFIZw?oc=5" t…
[Form 4] CARLSMED, INC. Insider Trading Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQemdyMjQ0R0VNdkJkQTdYVFhFYUMyc3l0NmdLYkxBaFI5Z0NYaFRvY1RGa3hDOTR3MnhUd2xmem13UG9yUGZTclRSXzlGbkJuam1mT2VpNjJUYlRNcUJ2UGljRHVRQmY3ZHU0SGZZX2NDb1BrOXZRaktnOGpNckduRU9qQUVqekNDQ3Bqek…
Possible Turnaround For Carlsmed Insiders, Still Down US$1.7m - Moomoo
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPQlJETUhla0J0QTg0b2o5c2dQc1FGZld0Z0pob2MxRU85ZUM4MEpfa3RfZWp1REtxYW9yQ0xjRnFxQl9uS2kwNFI3SzdoNmZiUENNMVZOcUdZc2NDc01vWmxjaWRvN0JxQmNLMXJYTUV6Mnl0ZnlCeUFvWF9zWDB1U2xQdUpEMC0wTWt3b3…
Carlsmed (CARL) Stock Forecast and Price Target 2026 $CARL - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFA2LVI3SHhlSjZMTFNEanlLRVpGX25RWTVmbHhOM3FWZWV4eGNGVmtYSHY2aW1jaXRfclhmUlZ3c1puX19POTlhbFl0RFhVTi1PR0tONWR3RDNfblFxVEhZdl9mcG1VUQ?oc=5" target="_blank">Carlsmed (CARL) Stock Forecas…
Workday stock drops 5%+ after CEO Carl Eschenbach steps down - SiliconANGLE
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPVDBVZG1oOGNUdjgxZmtmcGlici1KVWlDUEdNTF9FVjNIbEduZHZDUko2VFUzV3pGcDBYbU15dmp5U2ozSm42eEc5Z2M4Z3o2bmdfc0RzZEdRZTVvZ05ZOThUcklEYUtWcDhMM2JKYS1DcTVNd1BBTmxQMFU0b1RZNkJJLThHYWpwd1h0ZA…
CARL — Frequently Asked Questions
What is the current share price of Carlsmed, Inc. (CARL)?
As of 2026-07-14 21:23 PDT, Carlsmed, Inc. (CARL) trades at $10.80 on NasdaqGS. Its 52-week range is $8.83 to $16.99.
What is the market capitalisation of CARL?
Carlsmed, Inc. (CARL) has a market capitalisation of $293.60M on NasdaqGS.
What is the P/E ratio of CARL?
CARL trades at a trailing price-to-earnings (P/E) ratio of -11.13. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.36.
What is the return on equity (ROE) of CARL?
CARL has a return on equity (ROE) of -52.43%. Its return on capital employed (ROCE) is -26.39%.
Is CARL a good stock to buy?
This page provides a data-driven analysis of Carlsmed, Inc. (CARL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.